MapLight Therapeutics (MPLT) Cash from Financing Activities (2024 - 2025)

MapLight Therapeutics (MPLT) reported Cash from Financing Activities of $272.0 million for Q4 2025, up 5439200.0% on a YoY basis from N/an in Q4 2024, and up 5439200.0% sequentially from $5000.0 in Q4 2024.

MapLight Therapeutics (MPLT) Cash from Financing Activities (2024 - 2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 2 years of Cash from Financing Activities data on file, last reported at $272.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 30.14 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 53,000.00
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 68.63 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 238.74 Mn
10 MapLight Therapeutics 314.07 Mn 314.07 Mn - 271.97 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 271.97 Mn
Dec 31, 2025 271.97 Mn
Dec 31, 2024 5,000.00
Dec 31, 2024 5,000.00